Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

HaemoAdsorption Nach Reanimation An ECMO (HANRAE)

10 sierpnia 2018 zaktualizowane przez: Universitätsklinikum Hamburg-Eppendorf

This study evaluates the use of an additional hemoadsorption device in adult patients undergoing veno-arterial extracorporal membrane oxygenation (ECMO) following cardiac arrest and cardiopulmonary resuscitation in respect to its effects on post resuscitation inflammatory syndrome.

At implantation of the ECMO the participants are going to be randomized into a treatment and a control group. The first will be outfitted with a polymer-based adsorption device implemented in the extracorporal circulation established by ECMO for 48h, the control group is going to be treated by ECMO and standard intensive care alone. To detect any significant differences in terms of inflammatory response and patient outcome the investigators will regularly determine the blood levels of certain cytokines in fixed intervalls. In addition, the investigators are going to compare secondary clinical outcome parameters like organ disfunction and 30d mortality.

Przegląd badań

Szczegółowy opis

Even after successful return of spontaneus circulation (ROSC), patients suffering a cardiac arrest with subsequent cardipulmonary resuscitation (CPR) are still facing a significant morbidity and mortality in the post-resuscitation phase. They are nowadays often subjected to extracorporal membrane oxygenation (ECMO), supplementing or even replacing cardiac and/or pulmonary function for a certain period in order to reduce the workload for these critical organs. However, as well as the initial ischemia/reperfusion damage, subsequent procedures create significant stress to the patients organism, causing severe inflammation and contributing to post-resuscitation single or multiple organ disfunction and/or failure.

Continously eliminating relevant mediators of inflammation by adsorption to a polymer-based material in extracorporal circulation has been shown to influence the course of this inflammatory syndrome in patients with severe infection and sepsis. Any relevant clinical studies evaluating the use of such a device in post-resuscitation care are still lacking, yet.

Therefore, in this study the investigators are going to test the hypothesis that such a device is capable of significantly altering the cytokine levels during and even shortly after a 48h treatment period in addition to the standard ECMO therapy all patients are going to receive. As a secondary outlook, the investigators are going to compare the clinical outcome of the patients in terms of major organ disfunction and overall 30d mortality.

At the time extracoporal circulation is established during or after CPR, all participants (n=40) are enrolled and randomized into a treatment and a control group. The extracorporal circulation over the ECMO device is then outfitted with a certified in line adsorption cartridge for the treatment group. Due to technical reasons, this cartridge has to be exchanged for another identical module after 24h of continuous treatment. Adsorption therapy is terminated after 48h. The control group is subjected to ECMO without any additional modules. Both groups are receiving standard intensive care during the course of the study. All diagnostic and therapeutic decisions with the exemption of those directly concerning the hemoadsorption and sampling protocol are at sole discretion of the clinical staff.

For both groups, blood samples are taken at time points 0,6,12,24,36,48,72h after establishment of ECMO or time of death, respectively. Relevant parameters are then determined in different diagnostic and research laboratories with/without sample preprocessing by the study personal in accordance with preanalytic requirements. All relevant clinical data is extracted from the digital patient data management system (PDMS).

Typ studiów

Interwencyjne

Zapisy (Oczekiwany)

40

Faza

  • Nie dotyczy

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

      • Hamburg, Niemcy, 20246
        • Rekrutacyjny
        • University Hospital Hamburg-Eppendorf
        • Kontakt:
          • Jens Kubitz, Prof. Dr.
          • Numer telefonu: +49 (0) 40 7410 - 52415
          • E-mail: j.kubitz@uke.de
        • Kontakt:

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat do 75 lat (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

All patients receiving a veno-arterial ECMO after cardiac arrest at the study site are eligible for the study. Thus, the criteria are defined by the SOP "ECMO bei Reanimation" of the University Heart Center Hamburg:

Inclusion Criteria:

  • observed cardiac arrest with initial hyperdynamic rhythm and sufficient primary resuscitation

Exclusion Criteria (absolute):

  • existing "do-not-resuscitate"-order from the patient/a priori palliative situation
  • severe trauma
  • severe acute bleeding due to any cause
  • confirmed or highly likely relevant and severe persistent neurologic impairment
  • severe limiting comorbidities with independent and relevant reduction of life expectancy (e.g. malignoma, preexistent heart failure syndrome, obstructive/restrictive lung disease, hepatic cirrhosis)

Exclusion Criteria (relative, at the discretion of the responsible provider):

  • severe initial lacacidosis
  • prolongued mechanical resuscitation (>30min)

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Brak (otwarta etykieta)

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: Treatment
Inclusion of an extracorporal in line adsorbing cartridge for 48h (with a cartridge exchange at 24h) post establishing ECMO in addition to standard post resuscitation intensive care
see arm description
Brak interwencji: Control
ECMO and standard post resuscitation intensive care without any additional module in extracorporal circulation

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
IL-6 at hour 6
Ramy czasowe: 6 hours post establishment of extracorporal membrane oxygenation (ECMO)
Blood levels of interleukine 6 will be compared between intervention and control group
6 hours post establishment of extracorporal membrane oxygenation (ECMO)
IL-6 at hour 12
Ramy czasowe: 12 hours post establishment of extracorporal membrane oxygenation (ECMO)
Blood levels of interleukine 6 will be compared between intervention and control group
12 hours post establishment of extracorporal membrane oxygenation (ECMO)
IL-6 at hour 24
Ramy czasowe: 24 hours post establishment of extracorporal membrane oxygenation (ECMO)
Blood levels of interleukine 6 will be compared between intervention and control group
24 hours post establishment of extracorporal membrane oxygenation (ECMO)
IL-6 at hour 48
Ramy czasowe: 48 hours post establishment of extracorporal membrane oxygenation (ECMO)
Blood levels of interleukine 6 will be compared between intervention and control group
48 hours post establishment of extracorporal membrane oxygenation (ECMO)
IL-6 at hour 72
Ramy czasowe: 72 hours post establishment of extracorporal membrane oxygenation (ECMO)
Blood levels of interleukine 6 will be compared between intervention and control group
72 hours post establishment of extracorporal membrane oxygenation (ECMO)
TNF-a at hour 6
Ramy czasowe: 6 hours post establishment of extracorporal membrane oxygenation (ECMO)
Blood levels of human tumor necrosis factor alpha will be compared between intervention and control group
6 hours post establishment of extracorporal membrane oxygenation (ECMO)
TNF-a at hour 12
Ramy czasowe: 12 hours post establishment of extracorporal membrane oxygenation (ECMO)
Blood levels of human tumor necrosis factor alpha will be compared between intervention and control group
12 hours post establishment of extracorporal membrane oxygenation (ECMO)
TNF-a at hour 24
Ramy czasowe: 24 hours post establishment of extracorporal membrane oxygenation (ECMO)
Blood levels of human tumor necrosis factor alpha will be compared between intervention and control group
24 hours post establishment of extracorporal membrane oxygenation (ECMO)
TNF-a at hour 48
Ramy czasowe: 48 hours post establishment of extracorporal membrane oxygenation (ECMO)
Blood levels of human tumor necrosis factor alpha will be compared between intervention and control group
48 hours post establishment of extracorporal membrane oxygenation (ECMO)
TNF-a at hour 72
Ramy czasowe: 72 hours post establishment of extracorporal membrane oxygenation (ECMO)
Blood levels of human tumor necrosis factor alpha will be compared between intervention and control group
72 hours post establishment of extracorporal membrane oxygenation (ECMO)

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
S1P
Ramy czasowe: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
Blood levels of sphingosine-1-phosphate will be compared between intervention and control group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
PCT
Ramy czasowe: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The serum levels of procalcitonine will be compared between intervention and control group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
CRP
Ramy czasowe: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The plasma levels of C-related peptide will be compared between intervention and control group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
Leukocytes
Ramy czasowe: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The number of leukocytes in simple blood count will be compared between intervention and control group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
BNP
Ramy czasowe: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The serum levels of n-terminal pro brain natriuretic peptide will be compared between intervention and control group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
Mean arterial pressure (MAP)
Ramy czasowe: Continuosly from enrollment to 72h post.
The mean arterial pressure as calculated automatically from the invasively measured arterial pressure curve will be compared between intervention and control group.
Continuosly from enrollment to 72h post.
Heart rate (HR)
Ramy czasowe: Continuosly from enrollment to 72h post.
The continuously monitored heart rate will be compared between intervention and control group.
Continuosly from enrollment to 72h post.
Central venous pressure (CVP)
Ramy czasowe: Continuosly from enrollment to 72h post.
The continuously and invasively measured mean central venous pressure will be compared between intervention and control group, if available.
Continuosly from enrollment to 72h post.
haemodynamically relevant medication
Ramy czasowe: Continuosly from enrollment to 72h post.
The continuous intake of the following drugs as chosen by discretion of the clinical staff is extracted from digital PDMS: Norepinephrine, Epinephrine, Dobutamin, inodilatators (Milrinon, Enoximon, Levosimendan)
Continuosly from enrollment to 72h post.
Trop
Ramy czasowe: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The serum levels of troponine T will be compared between intervention and control group
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
CK
Ramy czasowe: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The Plasma levels of creatinkinase will be compared between intervention and control group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
Myoglobine
Ramy czasowe: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The Serum levels of myoglobine will be compared between intervention and control group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
Hemoglobine
Ramy czasowe: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The total blood concentration of hemoglobine will be compared between intervention and control group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
Haptoglobine
Ramy czasowe: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The serum levels of haptoglobine will be compared between intervention and control group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
paO2
Ramy czasowe: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The arterial partial pressure of oxygen as measured by point-of-care blood gas analysis is going to be compared between intervention and control group
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
paCO2
Ramy czasowe: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The arterial partial pressure of carbon dioxide as measured by point-of-care blood gas analysis is going to be compared between intervention and control group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
SaO2
Ramy czasowe: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The saturation of hemoglobine with oxygen in an arterial blood sample as measured by point-of-care blood gas analysis is going to be compared between intervention and control group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
SvO2
Ramy czasowe: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The saturation of hemoglobine with oxygen in a central venous blood sample as measured by point-of-care blood gas analysis is going to be compared between intervention and control group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
Horowitz index
Ramy czasowe: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The Horowitz index, calculated as paO2/FiO2 is going to be compared between intervention and control group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
pH
Ramy czasowe: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The pH of an arterial blood sample is going to be compared between intervention and control group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
HCO3
Ramy czasowe: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The levels of bicarbonate of an arterial blood sample are going to be compared between intervention and control group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
BE
Ramy czasowe: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The base excess of an arterial blood sample is going to be compared between intervention and control group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
N
Ramy czasowe: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The blood levels of sodium are going to be compared between intervention and control group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
K
Ramy czasowe: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The blood levels of potassium are going to be compared between intervention and control group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
C
Ramy czasowe: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The blood levels of chloride are going to be compared between intervention and control group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
Lactate
Ramy czasowe: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The blood levels of lactate are going to be compared between intervention and control group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
Mode of Ventilation
Ramy czasowe: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The mode of mechanical ventilation is going to be compared between intervention and control group
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
FiO2
Ramy czasowe: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The inspiratory oxygen fraction at mechanical ventilation is going to be compared between intervention and control group
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
Peak inspiratory pressure (pmax)
Ramy czasowe: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The peak inspiratory pressure at mechanical ventilation is going to be compared between intervention and control group
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
PEEP
Ramy czasowe: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The positive end exspiratory pressure at mechanical ventilation is going to be compared between intervention and control group
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
Ventilation frequency
Ramy czasowe: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The frequency of mechanical ventilation (cycles/min) is going to be compared between intervention and control group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
Tidal volume
Ramy czasowe: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The tidal volume achieved by mechanical ventilation is going to be compared between intervention and control group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
Total minute ventilation
Ramy czasowe: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The total minute ventilation as measured by the ventilation unit is going to be compared between intervention and control group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
Complicance
Ramy czasowe: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The airway compliance (c) as calculated from ventilator driving pressure(dp=pmax-PEEP) and tidal volume (V): c=V/dp is going to be compared between intervention and control group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
ASAT
Ramy czasowe: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The plasma levels of asparic acid aminotransferase will be compared between intervention and treatment group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
ALAT
Ramy czasowe: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The plasma levels of alanin aminotransferase will be compared between intervention and treatment group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
INR
Ramy czasowe: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The thrombin time as standardized international normal ratio will be compared between intervention and treatment group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
apTT
Ramy czasowe: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The activated partial thromboplastin time will be compared between intervention and treatment group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
Crea
Ramy czasowe: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The plasma creatinine concentration will be compared between intervention and treatment group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
eGFR
Ramy czasowe: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The glomerulary filtration rate, estimated from serum creatinine by the CKP-EPI formula will be compared between intervention and treatment group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
Volume status
Ramy czasowe: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
For a clinical estimation of the renal function, the following parameters are extracted from the digital PDMS: Fluid intake, diuresis, additional loss of body fluids (e.g. gastral reflux, vomitting, extraction by kidney replacement therapy)
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
NSE
Ramy czasowe: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The serum levels of neuron specific enolase will be compared between intervention and treatment group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
Mortality
Ramy czasowe: 30 days post enrollment
Mortality within 30 days after enrollment due to any cause will be determined, if follow up is technically feasible
30 days post enrollment

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Śledczy

  • Główny śledczy: Jens Kubitz, Prof. Dr., Universitätsklinikum Hamburg-Eppendorf

Publikacje i pomocne linki

Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.

Publikacje ogólne

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Oczekiwany)

1 października 2018

Zakończenie podstawowe (Oczekiwany)

1 maja 2019

Ukończenie studiów (Oczekiwany)

1 września 2019

Daty rejestracji na studia

Pierwszy przesłany

3 maja 2018

Pierwszy przesłany, który spełnia kryteria kontroli jakości

10 sierpnia 2018

Pierwszy wysłany (Rzeczywisty)

16 sierpnia 2018

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

16 sierpnia 2018

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

10 sierpnia 2018

Ostatnia weryfikacja

1 sierpnia 2018

Więcej informacji

Terminy związane z tym badaniem

Dodatkowe istotne warunki MeSH

Inne numery identyfikacyjne badania

  • UKEHANRAE

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

NIE

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Tak

produkt wyprodukowany i wyeksportowany z USA

Tak

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj